Australia is anticipating the arrival of Retatrutide, a groundbreaking medication by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, demonstrates significant efficacy in clinical trials, https://listfav.com/story23842463/this-new-drug-retatrutide-australia-a-new-solution-for-obesity-treatment